Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J.-M. | - |
dc.contributor.author | Noh, J. | - |
dc.contributor.author | Park, J.-W. | - |
dc.contributor.author | Chung, H. | - |
dc.contributor.author | Kim, K.-A. | - |
dc.contributor.author | Park, S.B. | - |
dc.contributor.author | Lee, J.-S. | - |
dc.contributor.author | Park, J.-Y. | - |
dc.date.accessioned | 2022-03-03T03:42:44Z | - |
dc.date.available | 2022-03-03T03:42:44Z | - |
dc.date.created | 2022-03-03 | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/137579 | - |
dc.description.abstract | Dabigatran (DAB) is an orally administered thrombin inhibitor. Both DAB and its main metabolite dabigatran acylglucuronide (DABG) have established anticoagulant effects. Here, we aimed to compare the relative anticoagulant effects of DABG and DAB in humans. Anticoagulant effects of DAB and DABG were measured in vitro using a thrombin generation assay. Additionally, their effects on other coagulation assays including PT, aPTT, TT, and fibrinogen were compared. Both DAB and DABG showed inhibitory effects on thrombin generation in a dose-dependent manner, but DABG exhibited a weaker inhibitory effect than that of DAB. The IC50 values of DAB and DABG on thrombin generation AUC were 134.1 ng/mL and 281.9 ng/mL, respectively. DABG also exhibited weaker anticoagulant effects than DAB on PT, aPTT, and TT. The results of the present study indicate that the anticoagulant effect of DABG, a main active DAB metabolite, is weaker than that of DAB. © 2022 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, J.-S. | - |
dc.identifier.doi | 10.3390/pharmaceutics14020257 | - |
dc.identifier.scopusid | 2-s2.0-85124088605 | - |
dc.identifier.wosid | 000764607300001 | - |
dc.identifier.bibliographicCitation | Pharmaceutics, v.14, no.2 | - |
dc.relation.isPartOf | Pharmaceutics | - |
dc.citation.title | Pharmaceutics | - |
dc.citation.volume | 14 | - |
dc.citation.number | 2 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | THROMBIN INHIBITOR DABIGATRAN | - |
dc.subject.keywordPlus | SODIUM-CITRATE CONCENTRATION | - |
dc.subject.keywordPlus | LABORATORY ASSESSMENT | - |
dc.subject.keywordPlus | ACTIVE METABOLITES | - |
dc.subject.keywordPlus | ETEXILATE | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | PHARMACODYNAMICS | - |
dc.subject.keywordPlus | 3.2-PERCENT | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | GENOTYPE | - |
dc.subject.keywordAuthor | Anticoagulation | - |
dc.subject.keywordAuthor | Dabigatran | - |
dc.subject.keywordAuthor | Dabigatran acylglucuronide | - |
dc.subject.keywordAuthor | Thrombin generation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.